TEVA — Recent News Coverage

Teva Pharmaceutical experienced a notable weekly rally, driven primarily by a catalyst beyond standard Q2 earnings results. While the company reported quarterly financials, the stock's upward momentum suggests market pa…

Teva Pharmaceutical reported Q2 2026 earnings on July 29, marking a routine quarterly disclosure for the generic and specialty pharma manufacturer. Earnings calls serve as primary mechanisms for management guidance upda…

Teva Pharmaceutical delivered positive momentum by raising its revenue guidance, signaling improved operational confidence or favorable market conditions. This contrasts sharply with the broader TASE index, which contin…

Teva Pharmaceutical reported a Q2 net loss of $576 million ($0.49/share), a significant swing from prior-year profitability of $282 million. While the quarterly deterioration signals operational headwinds, the stock's p…

Teva Pharmaceutical appears to be executing a meaningful operational turnaround, with leadership citing a blockbuster-potential asset in the pipeline as the primary catalyst for further upside. The framing suggests the …

Mega Or, an Israeli real estate and data center operator, faced headwinds today as regulatory delays in data center permits created near-term uncertainty for expansion plans. The halt signals infrastructure bottlenecks …

Teva Pharmaceutical continues its downward momentum, a pattern that reflects broader sector weakness in generic pharmaceuticals and ongoing market skepticism about the company's operational trajectory. The stock's persi…

The Tel Aviv Stock Exchange (TASE) experienced a significant intraday reversal, with the Banking Index surging 5.2% despite an initial steep correction. This rally suggests institutional repositioning and renewed confid…

Teva Pharmaceutical announced positive Phase Ib efficacy data for its anti-IL-15 antibody candidate in vitiligo treatment over a 24-week period. This represents a meaningful advancement in the company's pipeline for an …

TEVA has released Phase Ib clinical trial data for its anti-IL-15 antibody candidate targeting vitiligo, demonstrating efficacy over a 24-week period. The company's planned progression to Phase 2b trials represents a me…

Teva Pharmaceutical announced positive clinical trial results for a dermatological treatment targeting vitiligo, a chronic autoimmune pigmentation disorder affecting millions globally. The study demonstrated measurable …

Eli Lilly (LLY) and Teva Pharmaceutical (TEVA) represent divergent positioning within the pharma landscape, reflecting structural differences in growth trajectory and valuation. LLY commands a 33x forward earnings multi…

TEVA has attracted analyst attention following a recent share pullback, with Jefferies maintaining conviction on the stock. The analyst's maintained Buy rating and $40 price target suggest the market may have overshot t…

Teva Pharmaceutical (TEVA) disclosed positive clinical and real-world evidence for Austedo and Austedo XR, its neurology-focused medications. This announcement reinforces the company's portfolio expansion in the weight …